A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST）

PHASE3RecruitingINTERVENTIONAL

Enrollment

338

Participants

Timeline

Start Date

May 28, 2025

Primary Completion Date

October 31, 2028

Study Completion Date

April 30, 2032

Conditions

NSCLCAdjuvant Treatment

Interventions

DRUG

Firmonertinib

Firmonertinib: 240 mg, QD, orally

DRUG

Placebo

Placebo: 240 mg, QD, orally

Trial Locations (2)

RECRUITING

Peking University People's Hospital, Beijing

RECRUITING

Sun Yat-sen University Cancer Center, Guangdong